Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

(2012) W. Reinisch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

(2009) Klaus Bendtzen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

(2008) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY